Business Wire5h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Horizon Kinetics Q4 2024 Commentary
Horizon Kinetics have published their Q4 2024 Commentary. How’d we do? How’d the market do? What to expect now? Click here to ...
optometryadvisor11h
BP and IOP Predict RNFL Thinning in Moderate-to- Severe Glaucoma
A combination of low blood pressure and high intraocular pressure can predict RNFL thinning in moderate-to-severe glaucoma.
Supernus Pharmaceuticals, Inc.: Supernus Announces FDA Approval of ONAPGO (apomorphine hydrochloride) for Parkinson's Disease
ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...
openheart.bmj7h
Revealing the limitations of 10-year MACE observations: 20-year observed total cardiovascular burden in the EPIC-Norfolk study
Background Primary prevention strategies for cardiovascular disease (CVD) conventionally rely on 10-year risk estimates of ...
Hosted on MSN9h
The Best Camping Tents of 2025
Make the most of your home away from home by choosing the best camping tent for your adventure. We found the top car camping ...